We are truly in an “era of injectables,” with access to a varied armamentarium of products that yield dramatic aesthetic results with minimal recovery downtime. From its first published mention as an aesthetic treatment for glabellar lines in 1992, the use of commercially available BoNT type A (BoNTA) has captivated healthcare professionals and lay people alike. The availability of newer BoNTA formulations, with more expected in the near future, poses an exciting opportunity for aesthetic practitioners to reach an ever expanding potential patient base and provide increasingly refined treatment. Critical to this endeavor, is the ability to use BoNTA to its best effect; this requires, at minimum, an understanding of the scientific profile and physical characteristics of commercially available agents, but just as important are an understanding of the patient-specific factors that will determine the treatment plan. In addition, the ability to integrate consideration of each patient’s individual needs into the development of a personalized treatment strategy.